|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delay due to neutropenia was higher in patients who received granulocyte-colony stimulating factor on day 1.
|
31042138 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated a retrospective cohort of 228 adult lung transplant recipients between 2008 and 2013 to assess the association of neutropenia and granulocyte colony-stimulating factor (GCSF) treatment with outcomes.
|
31452317 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
He responded well to filgrastim (Neupogen) and blood transfusions, so a drug-related cause of neutropenia has been suspected.
|
31142911 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of granulocyte colony-stimulating factor can be beneficial to shorten the duration of neutropenia.
|
31842164 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delays due to neutropenia and leukopenia were significantly decreased among patients that received G-CSF (OR 0.098, 95% CI 0.06-0.15 and OR 0.32, 95% CI 0.18-0.58, respectively).<b>Discussion:</b> In conclusion, G-CSF support reduces neutropenic events and permits increased relative dose intensity, which is essential for improved survival outcomes.
|
31583943 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is widely used for prophylaxis and treatment of neutropenia in cancer patients and also for peripheral blood stem cells (PBSC) mobilization.
|
31003920 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with G-CSF could eventually be stopped, and the neutropenia, ultimately transient in nature, completely resolved.
|
30633375 |
2019 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with WHIM syndrome are often treated with granulocyte colony-stimulating factor (G-CSF), which can increase neutrophil counts but does not affect cytopenias other than neutropenia.
|
30625055 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia.
|
30727980 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current guidelines (GL) recommend neutropenia prophylaxis with G-CSF after chemotherapy (CTX) for patients with high (≥ 20%), or, if additional risk factors are present, intermediate (≥ 10-20%) risk of febrile neutropenia.
|
30374765 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein commonly used in the field of medicine to treat neutropenia.
|
30497339 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients received subcutaneous filgrastim as part of the prophylaxis regimen for neutropenia.
|
31623097 |
2019 |
|
Neutropenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Bone marrow progenitor cell colony-forming unit (CFU) count, serum cytokine levels, and peripheral leukocyte count after HIPEC and IP chemotherapy were compared.<b>Results:</b> Peripheral neutrophil count, cytokine (G-CSF and CXCL1/KC) levels, and bone marrow progenitor cell CFU count were significantly higher after HIPEC than after IP chemotherapy.<b>Conclusions:</b> Hyperthermia increased the serum neutrophil-recruiting cytokine levels and reduced the magnitude of chemotherapy-induced neutropenia.
|
31818168 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients received granulocyte colony-stimulating factor if they experienced grade 3/4 neutropenia or febrile neutropenia during any cycle.
|
30581162 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Twenty-eight (19%) patients were treated with peg-filgrastim as primary prophylaxis, while 74 (64%) received filgrastim "on demand" due to neutropenia.
|
31152919 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides, in duration of neutropenia after the same mass injection GX-G3 showed about 3.3 days of reduction effect compared with that of filgrastim, and 1.3 days of reduction effect compared with that of pegfilgrastim in neutropenia-induced rats.
|
31294492 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted this review of neutropenia in BTHS to aid in the diagnosis of this disease, and to improve understanding of both the consequences of neutropenia and the benefits of treatment with granulocyte colony-stimulating factor (G-CSF).
|
30451719 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exposure-safety analyses supported the recommended brentuximab vedotin starting dose (1.2 mg/kg every 2 weeks), and effective management of peripheral neuropathy and neutropenia with dose modification/reduction and febrile neutropenia with granulocyte colony-stimulating factor primary prophylaxis.
|
31152605 |
2019 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Only one patient experienced grade 3 neutropenia (3%), two patients grade 3 anemia (6%), and one patient grade 3 fatigue (3%); three patients were treated with prophylactic Granulocyte colony-stimulating factor (9%).
|
31356228 |
2019 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis suggested that grade 4 neutropenia associated significantly with an hmz UGT1A1 genotype [odds ratio (OR) 11.3; P = 0.04] and administration of granulocyte colony-stimulating factor (G-CSF) before the neutrophil counts dropped to < 500 cells/µL (OR; P = 0.01).
|
30328531 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This includes real-world data from MONITOR-GCSF, a multicenter, prospective, observational study describing treatment patterns and clinical outcomes of patients with cancer (n = 1447) receiving biosimilar filgrastim for the prophylaxis of chemotherapy-induced neutropenia in solid tumors and hematological malignancies.
|
31440986 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sandoz biosimilar filgrastim was approved based on Phase III confirmatory studies conducted in patients with breast cancer experiencing chemotherapy-induced neutropenia, with other indications granted based on extrapolation.
|
31405784 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Administration of granulocyte colony-stimulating factor is being used for neutropenia prophylaxis, but there are patients who develop neutropenia or febrile neutropenia despite prophylaxis.
|
30997742 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of G-CSF improves patient survival and reduces the rate of neutropenia complications.
|
31798380 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is commonly administered to prevent serious complications caused by chemotherapy-induced neutropenia; however, several cases of arteritis following the administration of G-CSF have been reported.
|
31090035 |
2019 |